Parameter | Overall survival | Disease-free survival | Survival from recurrence | |||||
---|---|---|---|---|---|---|---|---|
 | 5-year | Hazard ratio (95% CI) | p value | 5-year | Hazard ratio (95% CI) | p value | Hazard ratio (95% CI) | p value |
Axillary metastases | Â | Â | Â | Â | Â | Â | Â | Â |
   No | 71% | 1.0 | <0.0001 | 65% | 1.0 | <0.0001 | 1.0 | 0.32 |
   Yes | 51% | 1.83 (1.44–2.33) |  | 41% | 1.83 (1.45–2.32) |  | 1.17 (0.86–1.57) |  |
Tumour size | Â | Â | Â | Â | Â | Â | Â | Â |
   p1 | 89% | 1.0 | 0.002 | 70% | 1.0 | 0.0005 | 1.0 | 0.26 |
   p2 | 61% | 1.54 (0.92–2.62) |  | 54% | 1.49 (0.90–2.48) |  | 1.09 (0.60–1.96) |  |
   p3 | 46% | 2.18 (1.25–3.82) |  | 35% | 2.20 (1.28–3.79) |  | 1.29 (0.69–2.41) |  |
ER | Â | Â | Â | Â | Â | Â | Â | Â |
   Positive | 64% | 1.0 | 0.68 | 52% | 1.0 | 0.74 | 1.0 | <0.0001 |
   Negative | 52% | 1.05 (0.83–1.33) |  | 48% | 0.96 (0.76–1.21) |  | 2.1 (1.59–2.79) |  |
PR | Â | Â | Â | Â | Â | Â | Â | Â |
   Positive | 64% | 1.0 | 0.82 | 49% | 1.0 | 0.55 | 1.0 | 0.005 |
   Negative | 56% | 1.03 (0.80–1.33) |  | 52% | 0.93 (0.72–1.19) |  | 1.51 (1.13–2.02) |  |
Age in years | Â | Â | Â | Â | Â | Â | Â | Â |
   <35 | 53% | 1.0 | 0.002 | 39% | 1.0 | 0.01 | 1.0 | 0.96 |
   35–50 | 58% | 0.90 (0.57–1.41) |  | 50% | 0.99 (0.63–1.55) |  | 0.89 (0.57–1.39) |  |
   50–65 | 64% | 0.81 (0.52–1.26) |  | 57% | 0.85 (0.55–1.31) |  | 0.89 (0.57–1.38) |  |
   >65 | 54% | 1.44 (0.90–2.30) |  | 44% | 1.39 (0.87–2.23) |  | 0.89 (0.52–1.50) |  |
CK14 | Â | Â | Â | Â | Â | Â | Â | Â |
   Negative | 59% | 1.0 | 0.02 | 49% | 1.0 | 0.005 | 1.0 | 0.001 |
   Positive | 60% | 0.69 (0.50–0.94) |  | 56% | 0.65 (0.48–0.88) |  | 1.84 (1.27–2.65) |  |
CK14 pattern | Â | Â | Â | Â | Â | Â | Â | Â |
   Negative | 59% | 1.0 | 0.005 | 49% | 1.0 | 0.003 | 1.0 | 0.002 |
   Focal | 50% | 0.92 (0.65–1.28) |  | 48% | 0.83 (0.59–1.16) |  | 2.31 (1.54–3.45) |  |
   Diffuse | 88% | 0.31 (0.15–0.63) |  | 79% | 0.32 (0.17–0.63) |  | 0.84 (0.35–2.06) |  |